Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone

Lignende værker

• Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
  af: Pepe, Alessia, et al.
  Udgivet: (2011)
• Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia
  af: F. Rashidi ghader, M.D, et al.
  Udgivet: (2007-01-01)
• A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
  af: Pepe, Alessia, et al.
  Udgivet: (2011)
• A novel mutation in the erythroid transcription factor KLF1 is likely responsible for ameliorating β‐thalassemia major
  af: Fanis, Pavlos, et al.
  Udgivet: (2019)
• Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone)
  af: Wali, Yasser, et al.
  Udgivet: (2008)